Dermapharm Holding SE (DMP.DE)

EUR 39.2

(1.82%)

Operating Expenses Summary of Dermapharm Holding SE

Dermapharm Holding SE's latest annual operating expenses in 2023 was 142.51 Million EUR , down -65.97% from previous year.
Dermapharm Holding SE's latest quarterly operating expenses in 2024 Q2 was 40.37 Million EUR , down -2.68% from previous quarter.
Dermapharm Holding SE reported a annual operating expenses of 418.78 Million EUR in annual operating expenses 2022, up 25.52% from previous year.
Dermapharm Holding SE reported a annual operating expenses of 333.65 Million EUR in annual operating expenses 2021, up 4.85% from previous year.
Dermapharm Holding SE reported a quarterly operating expenses of 41.48 Million EUR for 2024 Q1, down -0.44% from previous quarter.
Dermapharm Holding SE reported a quarterly operating expenses of 123.84 Million EUR for 2023 Q3, down -15.12% from previous quarter.

Annual Operating Expenses Chart of Dermapharm Holding SE (2023 - 2014)

Historical Annual Operating Expenses of Dermapharm Holding SE (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	142.51 Million EUR	-65.97%
2022	418.78 Million EUR	25.52%
2021	333.65 Million EUR	4.85%
2020	318.21 Million EUR	20.54%
2019	263.97 Million EUR	38.28%
2018	190.9 Million EUR	46.11%
2017	130.65 Million EUR	13.68%
2016	114.93 Million EUR	2.47%
2015	112.16 Million EUR	-11.55%
2014	126.8 Million EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	40.37 Million EUR	-2.68%
2024 Q1	41.48 Million EUR	-0.44%
2023 Q3	123.84 Million EUR	-15.12%
2023 Q4	41.66 Million EUR	-66.35%
2023 FY	142.51 Million EUR	-65.97%
2023 Q1	128.08 Million EUR	3.59%
2023 Q2	145.9 Million EUR	13.92%
2022 Q1	88.53 Million EUR	-8.34%
2022 FY	418.78 Million EUR	25.52%
2022 Q2	119.18 Million EUR	34.61%
2022 Q4	123.64 Million EUR	41.43%
2022 Q3	87.42 Million EUR	-26.65%
2021 Q4	96.58 Million EUR	34.26%
2021 FY	333.65 Million EUR	4.85%
2021 Q2	83.48 Million EUR	2.27%
2021 Q3	71.94 Million EUR	-13.83%
2021 Q1	81.63 Million EUR	-6.41%
2020 Q4	87.22 Million EUR	7.29%
2020 FY	318.21 Million EUR	20.54%
2020 Q3	81.29 Million EUR	-2.23%
2020 Q2	83.14 Million EUR	24.95%
2020 Q1	66.54 Million EUR	-6.17%
2019 Q2	62.91 Million EUR	0.82%
2019 FY	263.97 Million EUR	38.28%
2019 Q1	62.4 Million EUR	17.42%
2019 Q4	70.91 Million EUR	4.71%
2019 Q3	67.72 Million EUR	7.64%
2018 Q4	53.14 Million EUR	13.19%
2018 FY	190.9 Million EUR	46.11%
2018 Q2	47.71 Million EUR	10.78%
2018 Q1	43.07 Million EUR	10.56%
2018 Q3	46.95 Million EUR	-1.6%
2017 Q2	32.05 Million EUR	2.77%
2017 Q3	28.44 Million EUR	-11.28%
2017 Q1	31.19 Million EUR	-4.85%
2017 FY	130.65 Million EUR	13.68%
2017 Q4	38.96 Million EUR	36.98%
2016 FY	114.93 Million EUR	2.47%
2016 Q4	32.78 Million EUR	0.0%
2015 FY	112.16 Million EUR	-11.55%
2014 FY	126.8 Million EUR	0.0%

Peer Operating Expenses Comparison of Dermapharm Holding SE

Name	Operating Expenses	Operating Expenses Difference
MPH Health Care AG	4.22 Million EUR	-3275.848%
Apontis Pharma AG	23.17 Million EUR	-515.066%
Evotec SE	222.55 Million EUR	35.965%
MERCK Kommanditgesellschaft auf Aktien	8.82 Billion EUR	98.385%
PharmaSGP Holding SE	50.72 Million EUR	-180.965%
SynBiotic SE	1.5 Million EUR	-9360.455%